Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.

Breast cancer research and treatment - 1 Feb 2015

Wong-Brown Michelle W, Meldrum Cliff J, Carpenter Jane E, Clarke Christine L, Narod Steven A, Jakubowska Anna, Rudnicka Helena, Lubinski Jan, Scott Rodney J

Abstract excerpt

Triple-negative breast cancers (TNBC) lack expression of oestrogen, progesterone and HER2 receptors. The gene expression profiles of TNBCs are similar to those of breast tumours in women with BRCA1 mutations. Reports to date indicate that up to 20 % of TNBC patients harbour germline BRCA mutations; however, the prevalence of BRCA mutations in TNBC patients varies widely between countries and from study to study....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Australia
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Neoplasm Grading

Share to Neoplasm Metastasis

Share to Ovarian Neoplasms

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 25682074
DOI: 10.1007/s10549-015-3293-7

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.PMID 25682074Read ↗

Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.Semantic proximity Read ↗

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer historySemantic proximity Read ↗

Germline Mutations in Triple-Negative Breast CancerSemantic proximity Read ↗

Therapeutic landscape in mutational triple negative breast cancerSemantic proximity Read ↗

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations and their clinical relevance in selected women diagnosed with triple-negative breast cancer in Kenya: a descriptive cross-sectional study.Semantic proximity Read ↗

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.Semantic proximity Read ↗

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.Semantic proximity Read ↗

Identification of Somatic and Germline Mutations Influencing Treatment Outcomes and Disease Susceptibility in Tunisian Triple-Negative Breast Cancer Using Next-Generation Sequencing.Semantic proximity Read ↗

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.Semantic proximity Read ↗

Prevalence of <i>BRCA</i> mutations in an unselected population of triple‐negative breast cancerSemantic proximity Read ↗

Contribution of BRCA1 5382insC mutation in triple negative breast cancer in TunisiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.